Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting
Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Among Parkinson’s disease patients with both OFF and dyskinesia, ADS-5102 (amantadine) extended-release reduces disruptive motor episodes and improves function: Analysis of phase 3 trials
Objective: Evaluate the effects of ADS-5102 (amantadine) extended release capsules on motor complications and functional outcomes among patients experiencing both troublesome dyskinesia and OFF (disruptive…Efficacy of opicapone compared to entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: A post-hoc conservative analysis
Objective: To assess the efficacy of opicapone 50 mg (OPC 50 mg), compared with entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients recently…A pilot study on the efficacy, tolerability and safety of safinamide in elderly Parkinson’s disease patients
Objective: The aim of the study is to evaluate the efficacy, safety and tolerability of SF (50 and 100 mg / day) in elderly patients…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL-130277; APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and…Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) as first-line adjunctive therapy in levodopa/DOPA decarboxylase inhibitors-treated Parkinson’s disease (PD) patients…High levodopa plasma concentration in the acute levodopa challenge test predicts levodopa-induced dyskinesia in Parkinson’s disease
Objective: We aimed to investigate the correlation between levodopa pharmacokinetics and levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Background: In patients with PD, pulsatile dopaminergic…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in De Novo vs Rollover Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in de novo (DN) vs…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 34
- Next Page »